8 research outputs found
Recommended from our members
Current challenges and future directions for engineering extracellular vesicles for heart, lung, blood and sleep diseases.
Extracellular vesicles (EVs) carry diverse bioactive components including nucleic acids, proteins, lipids and metabolites that play versatile roles in intercellular and interorgan communication. The capability to modulate their stability, tissue-specific targeting and cargo render EVs as promising nanotherapeutics for treating heart, lung, blood and sleep (HLBS) diseases. However, current limitations in large-scale manufacturing of therapeutic-grade EVs, and knowledge gaps in EV biogenesis and heterogeneity pose significant challenges in their clinical application as diagnostics or therapeutics for HLBS diseases. To address these challenges, a strategic workshop with multidisciplinary experts in EV biology and U.S. Food and Drug Administration (USFDA) officials was convened by the National Heart, Lung and Blood Institute. The presentations and discussions were focused on summarizing the current state of science and technology for engineering therapeutic EVs for HLBS diseases, identifying critical knowledge gaps and regulatory challenges and suggesting potential solutions to promulgate translation of therapeutic EVs to the clinic. Benchmarks to meet the critical quality attributes set by the USFDA for other cell-based therapeutics were discussed. Development of novel strategies and approaches for scaling-up EV production and the quality control/quality analysis (QC/QA) of EV-based therapeutics were recognized as the necessary milestones for future investigations.Funding information:
National Heart, Lung, and Blood Institute,
Grant/Award Numbers: HL 122596, HL124021,
HL124074, HL128297, HL141080, HL155346-01,
R35HL150807, R56HL141206
Prithu Sundd was supported by NIH-NHLBI R01 grants (HL128297 and HL141080) and 18TPA34170588 from American Heart
Association. Stephen Y. Chan was supported by NIH grants R01 HL124021 and HL 122596 as well as AHA grant 18EIA33900027.
SuamyaDaswas supported by NIH grants R35HL150807, UH3 TR002878 andAHASFRN35120123. ZhenjiaWangwas supported
by NIH grant (R01EB027078). Pilar Martín was supported by MCIN-ISCIII-Fondo de Investigación Sanitaria grant PI22/01759.
KennethW.Witwer was supported in part by NIH grants R01AI144997, R01DA047807, R33MH118164 andUH3CA241694. Tianji
Chen was supported by AHA Career Development Award 18CDA34110301, Gilead Sciences Research Scholars Program in PAH,
NIH-NHLBI grant R56HL141206 and Chicago Biomedical ConsortiumCatalyst Award. EduardoMarbán was supported byNIH
R01 HL124074 and HL155346-01.S
A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers
Immunotherapy for cancer has been a focus 50 years ago. At the time, this treatment was developed prior to cloning of the cytokines, no knowledge of regulatory T-cells, and very little information that mesenchymal stem cells (MSCs) (originally colony forming unit-fibroblasts [CFU-F]) could be licensed by the inflammatory microenvironment to suppress an immune response. Given the information available at that time, mononuclear cells from the peripheral blood were activated ex vivo and then replaced in the patients with tumor. The intent was to harness these activated immune cells to target the cancer cells. These studies did not lead to long-term responses because the activated cells when reinfused into the patients were an advantage to the resident MSCs, which can home the tumor and then become suppressive in the presence of the immune cells. The immune suppression caused by MSCs would also expand regulatory T-cells, resulting instead in tumor protection. As time progressed, these different fields converged into a new approach to use immunotherapy for cancer. This article discusses these approaches and also reviews chimeric antigen receptor in the context of future treatments for solid tumors, including breast cancer
Surveying the experience of postdocs in the United States before and during the COVID-19 pandemic
In the interest of advocating for the postdoctoral community in the United States (US), we compared the results of surveys of postdocs carried out in 2019 and in late 2020. We found that respondents’ mental health and wellness were significantly impacted by the pandemic irrespective of their gender, race, citizenship, or other identities. Career trajectories and progression were also affected, as respondents reported being less confident about achieving career goals, and having more negative perceptions of the job market compared to before the pandemic. Postdocs working in the US on temporary visas reported experiencing increased stress levels due to changes in immigration policy. Access to institutional Postdoctoral Offices or Associations positively impacted well-being and helped mitigate some of the personal and professional stresses caused by the pandemic
Measuring H<sub>2</sub><sup>18</sup>O Tracer Incorporation on a QQQ-MS Platform Provides a Rapid, Transferable Screening Tool for Relative Protein Synthesis
Intracellular proteins are in a state of flux, continually
being
degraded into amino acids and resynthesized into new proteins. The
rate of this biochemical recycling process varies across proteins
and is emerging as an important consideration in drug discovery and
development. Here, we developed a triple-stage quadrupole mass spectrometry
assay based on product ion measurements at unit resolution and H<sub>2</sub><sup>18</sup>O stable tracer incorporation to measure relative
protein synthesis rates. As proof of concept, we selected to measure
the relative in vivo synthesis rate of ApoB100, an apolipoprotein
where elevated levels are associated with an increased risk of coronary
heart disease, in plasma-isolated very low density lipoprotein (VLDL)
and low density lipoprotein (LDL) in a mouse in vivo model. In addition,
serial time points were acquired to measure the relative in vivo synthesis
rate of mouse LDL ApoB100 in response to vehicle, microsomal triacylglycerol
transfer protein (MTP) inhibitor, and site-1 protease inhibitor, two
potential therapeutic targets to reduce plasma ApoB100 levels at 2
and 6 h post-tracer-injection. The combination of H<sub>2</sub><sup>18</sup>O tracer with the triple quadrupole mass spectrometry platform
creates an assay that is relatively quick and inexpensive to transfer
across different biological model systems, serving as an ideal rapid
screening tool for relative protein synthesis in response to treatment
Measuring H<sub>2</sub><sup>18</sup>O Tracer Incorporation on a QQQ-MS Platform Provides a Rapid, Transferable Screening Tool for Relative Protein Synthesis
Intracellular proteins are in a state of flux, continually
being
degraded into amino acids and resynthesized into new proteins. The
rate of this biochemical recycling process varies across proteins
and is emerging as an important consideration in drug discovery and
development. Here, we developed a triple-stage quadrupole mass spectrometry
assay based on product ion measurements at unit resolution and H<sub>2</sub><sup>18</sup>O stable tracer incorporation to measure relative
protein synthesis rates. As proof of concept, we selected to measure
the relative in vivo synthesis rate of ApoB100, an apolipoprotein
where elevated levels are associated with an increased risk of coronary
heart disease, in plasma-isolated very low density lipoprotein (VLDL)
and low density lipoprotein (LDL) in a mouse in vivo model. In addition,
serial time points were acquired to measure the relative in vivo synthesis
rate of mouse LDL ApoB100 in response to vehicle, microsomal triacylglycerol
transfer protein (MTP) inhibitor, and site-1 protease inhibitor, two
potential therapeutic targets to reduce plasma ApoB100 levels at 2
and 6 h post-tracer-injection. The combination of H<sub>2</sub><sup>18</sup>O tracer with the triple quadrupole mass spectrometry platform
creates an assay that is relatively quick and inexpensive to transfer
across different biological model systems, serving as an ideal rapid
screening tool for relative protein synthesis in response to treatment
Recommended from our members
Current challenges and future directions for engineering extracellular vesicles for heart, lung, blood and sleep diseases
Extracellular vesicles (EVs) carry diverse bioactive components including nucleic acids, proteins, lipids and metabolites that play versatile roles in intercellular and interorgan communication. The capability to modulate their stability, tissue-specific targeting and cargo render EVs as promising nanotherapeutics for treating heart, lung, blood and sleep (HLBS) diseases. However, current limitations in large-scale manufacturing of therapeutic-grade EVs, and knowledge gaps in EV biogenesis and heterogeneity pose significant challenges in their clinical application as diagnostics or therapeutics for HLBS diseases. To address these challenges, a strategic workshop with multidisciplinary experts in EV biology and U.S. Food and Drug Administration (USFDA) officials was convened by the National Heart, Lung and Blood Institute. The presentations and discussions were focused on summarizing the current state of science and technology for engineering therapeutic EVs for HLBS diseases, identifying critical knowledge gaps and regulatory challenges and suggesting potential solutions to promulgate translation of therapeutic EVs to the clinic. Benchmarks to meet the critical quality attributes set by the USFDA for other cell-based therapeutics were discussed. Development of novel strategies and approaches for scaling-up EV production and the quality control/quality analysis (QC/QA) of EV-based therapeutics were recognized as the necessary milestones for future investigations